VIDEO: KEYNOTE-966 study shows marginal benefit in biliary tract cancer
Click Here to Manage Email Alerts
In this video, Daneng Li, MD, a medical oncologist at City of Hope, discussed results from the phase 3 KEYNOTE-966 study, presented at American Association for Cancer Research Annual Meeting.
Li said the study — which tested a combination therapy of pembrolizumab (Keytruda, Merck) and gemcitabine/cisplatin in patients with biliary tract cancer and showed statistically significant progression-free survival — is only a small step forward.
“Personally, I think this benefit is really marginal,” Li said. “Are there other strategies we can think about with the incorporation of other agents that may synergize better with our immuno-oncology agents to possibly lead to better outcomes for our patients?”
Collapse
Read more about
Click Here to Manage Email Alerts